Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Yao JC, et al. Among authors: rouyrre n. Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17. Lancet. 2016. PMID: 26703889 Free PMC article. Clinical Trial.
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.
Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC. Pavel ME, et al. Among authors: rouyrre n. Ann Oncol. 2017 Jul 1;28(7):1569-1575. doi: 10.1093/annonc/mdx193. Ann Oncol. 2017. PMID: 28444114 Free PMC article. Clinical Trial.
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.
Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC. Pavel ME, et al. Among authors: rouyrre n. Ann Oncol. 2019 Dec 1;30(12):2010. doi: 10.1093/annonc/mdz222. Ann Oncol. 2019. PMID: 31406974 Free PMC article. No abstract available.
A proof of concept phase II non-inferiority criterion.
Neuenschwander B, Rouyrre N, Hollaender N, Zuber E, Branson M. Neuenschwander B, et al. Among authors: rouyrre n. Stat Med. 2011 Jun 15;30(13):1618-27. doi: 10.1002/sim.3997. Epub 2011 Feb 24. Stat Med. 2011. PMID: 21351286
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
Cree BA, Arnold DL, Fox RJ, Gold R, Vermersch P, Benedict RH, Bar-Or A, Piani-Meier D, Rouyrre N, Ritter S, Kilaru A, Karlsson G, Giovannoni G, Kappos L. Cree BA, et al. Among authors: rouyrre n. Mult Scler. 2022 Sep;28(10):1591-1605. doi: 10.1177/13524585221083194. Epub 2022 Apr 5. Mult Scler. 2022. PMID: 35380078 Free PMC article.
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
Cree BA, Magnusson B, Rouyrre N, Fox RJ, Giovannoni G, Vermersch P, Bar-Or A, Gold R, Piani Meier D, Karlsson G, Tomic D, Wolf C, Dahlke F, Kappos L. Cree BA, et al. Among authors: rouyrre n. Mult Scler. 2021 Sep;27(10):1564-1576. doi: 10.1177/1352458520971819. Epub 2020 Nov 18. Mult Scler. 2021. PMID: 33205682 Free PMC article. Clinical Trial.
17 results